V2.0 dated 25Jan2019
V2.0 dated 25Jan2019

V2.0 dated 25Jan2019
V2.0 dated 25Jan2019
V2.0 dated 25Jan2019
V2.0 dated 25Jan2019
V2.0 dated 25Jan2019
V2.0 dated 25Jan2019Post Progression Study Day:
Baseline:
Concomitant Medication
Discontinued Subject: 
Date of origin – survival analysis: 
End of Study
Enrolled Subjects
Most Frequently-Reported Treatment-Emergent Adverse Events:  
Screen Failures
The Sponsor
Time of origin (T 0)
Treated Population
Treatment-Emergent Adverse Event (TEAE)
V2.0 dated 25Jan2019
V2.0 dated 25Jan2019o
V2.0 dated 25Jan2019o
o
V2.0 dated 25Jan2019
V2.0 dated 25Jan2019
V2.0 dated 25Jan2019
V2.0 dated 25Jan2019
V2.0 dated 25Jan2019Visit numbe r 1, 6, 11, 1 62, 7, 12, 1 7 3, 8, 13, 18 4, 9, 14, 19 5, 10, 15, 2 0
V2.0 dated 25Jan2019
V2.0 dated 25Jan2019
V2.0 dated 25Jan2019®
® ®
V2.0 dated 25Jan2019®
V2.0 dated 25Jan2019
V2.0 dated 25Jan2019
V2.0 dated 25Jan2019
V2.0 dated 25Jan2019
V2.0 dated 25Jan2019
V2.0 dated 25Jan2019
V2.0 dated 25Jan2019®
.
Journal of the National Cancer Institute 
V2.0 dated 25Jan2019
V2.0 dated 25Jan2019
V2.0 dated 25Jan2019
V2.0 dated 25Jan2019
V2.0 dated 25Jan2019